TORRENT PHARMA
JEFFERIES ON TORRENT PHARMA : 19.05.2021
* Estimate of FY21-23 EPS CAGR of 17.2% for Torrent Pharma is driven by continued deleveraging, Jefferies says
* MAINTAIN UNDERPERFORM TARGET: 2,416
* FY22 Growth Will Be Driven By India Rebound In H1
* Co Expects US To Be Stable With Launches Compensating For Price Erosion
* Estimate Of FY21-23 EPS CAGR Of 17.2% Is Driven By Continued Deleveraging
